{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-026106","form_type":"8-K","ticker":"GALT","cik":"0001133416","company_name":"GALECTIN THERAPEUTICS INC","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.404241+00:00","generated_at":"2026-06-01T22:37:40.568011+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Galectin Therapeutics Q1 net loss $0.19/share; cash $23.6M; NAVIGATE trial on track for Q4 2024 interim data","bullets":["Net loss $11.5M ($0.19 per share) for Q1 2024, unchanged from Q1 2023.","Cash and equivalents $23.6M; additional $20M available from chairman's credit lines (two $10M facilities).","Fifth DSMB recommended continuation of NAVIGATE Phase 2b/3 trial of belapectin in MASH cirrhosis without modifications.","Interim top-line data from Phase 2b portion expected late Q4 2024.","Appointed Khurram Jamil, M.D. as Vice President of Clinical Development."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-026106","json":"https://secwatch.observer/filing/0001140361-24-026106.json","markdown":"https://secwatch.observer/filing/0001140361-24-026106.md","text":"https://secwatch.observer/filing/0001140361-24-026106.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133416/000114036124026106/0001140361-24-026106-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133416/000114036124026106/ef20028923_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T22:37:40.568011+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"98a14c155982650c627f300f2cfecf27ae7dbec5","claim":"GALECTIN THERAPEUTICS INC reported the quarter ended March 31, 2024 results: net income net loss of $11.5 million, EPS ($0.19) per share.","evidence_excerpt":"For the quarter ended quarter ended March 31, 2024, the Company reported a net loss applicable to common stockholders of $11.5 million, or ($0.19) per share, compared to a net loss applicable to common stockholders of $11.5 million, or ($0.19) per share for the quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1133416/000114036124026106/0001140361-24-026106-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Net income","value":"net loss of $11.5 million"},{"label":"EPS","value":"($0.19) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}